Slide 1: Investor presentation Q2 2021
Investor presentation Q2 2021 15 July, 2021 Cecilia Edström, CEO Gabriella Björknert Caracciolo, CFO
Slide 2: Business highlights - second quarter 2021
Business highlights - second quarter 2021 Major breakthrough with Zimmer Biomet and new partnerships for wound care LICENSE BUSINESS BACTIGUARD PORTFOLIO • CE-mark for orthopaedic trauma • New partnerships for Bactiguard implants from Zimmer Biomet in Wound Care: January, production start in April •
Slide 3: Bactiguard – second quarter 2021 Key Financials
Bactiguard – second quarter 2021 Key Financials Sales EBITDA Net Profit Operating cash flow MSEK 46.0 (48.2) License 31.6 (22.1) MSEK 1.8 (10.5) MSEK -12.0 (-0.3) MSEK 5.5 (3.6) BIP sales 13.3 (25.4)
Slide 4: Global outlook
Global outlook Covid-19 situation in Q2 • Centre of gravity has shifted to South • Over 180 million cases East Asia and MEA • More than 4 million deaths • Lock-downs affecting several countries • India stabilizing, but still facing enormous challenges • EU – gradually opening up, but increasing infe
Slide 5: Covid-19 affecting sales in the regions
Covid-19 affecting sales in the regions Medium to high global impact USA Nordics Recovery following massive vaccination programs. Europe, Health care opening up ahead of other countries. ex. Nordics Nordics & Europe USA Elective surgeries still low, but gradually catching up. Middle East, China Back
Slide 6: Acquisition paving the way for business development
Acquisition paving the way for business development 2021 Sept 2021 June Bactiguard wound 2020 February ZNN Bactiguard care launch D and ES 2021 Jan EMEA launch Aniocyn Bactiguard acquires Vigilenz ZNN Bactiguard Bactiguard Wound Nordic launch 2020 March CE mark Care launch Swe Hydrocyn disinfection
Slide 7: Zimmer Biomet EMEA launch
Zimmer Biomet EMEA launch Positioning of Bactiguard technology
Slide 8: Hospital acquired infections
Hospital acquired infections European market data Hospital acquired infections 3.2 million cases1 16 million extra hospital days2 Annual HAI related cost of hospital stays 2 7 billion Euro 65% of HAI cases related to biofilm 30% infection rate in orthopedic trauma 80% in open fracture cases 3,4,5 1.
Slide 9: Zimmer Biomet clinical trial
Zimmer Biomet clinical trial A multicenter study Summary • Patients with severe tibial fractures in need of intramedullary nail • 500 patients in total • Reduced infection after fracture fixation ü Primary endpoint: fracture related infection after 12 months ü Secondary endpoint: fracture healing, Q
Slide 10: Expanding infection prevention portfolio
Expanding infection prevention portfolio Hypochlorous acid DISINFECTION HYDROCYN BACTIGUARD WOUND CARE WOUND CARE ANIOCYN HYDROCYN WOUND CARE VETERINARY VIGILENZ CARE B2B 10
Slide 11: Hybrid distribution model
Hybrid distribution model • Developing our distribution Customer / Patient model • Broader product portfolio for infection prevention • Capitalise on the increasing Own sales force Distributor Bactiguard / Distributor need for infection Service Specialists prevention Demand Physical After-Sales • In
Slide 12: Financial update
Financial update 12
Slide 13: Stable revenues second quarter
Stable revenues second quarter Still negative COVID-19 impact on the business • Stable BD license revenues, negative currency effect • BIP revenues still negatively impacted by Covid-19. • New partnerships for Wound Care, first revenues in Q3 • New license revenue of MUSD 1, following Zimmer Biomet
Slide 14: Financial overview
Financial overview Q2 2021 (Q2 2020) • Organic revenue growth of 5%, reported -5% • EBITDA MSEK 1.8 (10.5) with an EBITDA-margin of 4% (22%). Higher EBITDA margin in Q2 2020 due to strong demand for disinfection related to Covid outbreak. • Net profit/loss: MSEK -12.0 (-0.3). Regular depreciation on
Slide 15: Cash flow and liquidity
Cash flow and liquidity MSEK • Positive operating cash flow in Q2, MSEK 5.5 (3.6). Working capital increased 4.8 (-6.9) due to increase of accounts receivables at the end of the period • Overdraft facility utilized by MSEK 14.3 (-) as of June 30 • Available liquidity MSEK 41.3, incl. overdraft facil
Slide 16: Strategic focus and value creation
Strategic focus and value creation Focus H2 LICENSE • Roll out of ZNN Bactiguard in EMEA, next step US and RoW BUSINESS • Multi-center clinical trials in long term applications - KOL network • Expanding into new applications – several interesting dialogues ongoing • Strengthening the team BACTIGUARD
Slide 17: Long term financial targets
Long term financial targets GROWTH PROFITABILITY DIVIDEND Average revenue growth of EDITDA margin of at least A long-term goal to achieve a 20% per year over a five 30% at the end of the five- dividend of 30-50% of profit year period from 2020 year period after tax, taking into consideration the com
Slide 18: Ten reasons to invest in Bactiguard
Bactiguard infection prevention – New standard of care Ten reasons to invest in Bactiguard Long-term owners and dedicated management 10 1 Contribution to the UN’s Global Sustainable Development Goal. Bactiguard’s Profitable growth 9 2 technology is effective and safe Infection prevention a central c
Slide 19: Bactiguard on the outside – safe on the inside
Bactiguard on the outside – safe on the inside 19
Slide 20: Questions & Answers
Questions & Answers Cecilia Edström Gabriella Björknert Caracciolo CEO CFO +46 8 440 58 80 +46 8 440 58 80 cecilia.edstrom@bactiguard.com gabriella.caracciolo@bactiguard.com 20
Slide 21: Upcoming events and financial reports
Upcoming events and financial reports October 28, 2021 • Q3, 2021 21